BD Expands Capacity for Advanced Prefillable Syringes and Enhances Injection Experience for the Next Generation of Biologics
BD (NYSE: BDX) has announced the commercial release of the BD Neopak™ XtraFlow™ Glass Prefillable Syringe and expanded capacity for its BD Neopak™ Glass Prefillable Syringe platform. This expansion aims to serve the growing biologics market, with the platform already approved for over 24 indications. The XtraFlow™ syringe features an 8mm needle and thinner wall cannula, optimizing delivery of high-viscosity drugs by reducing injection force and time.
BD has also integrated a high-volume manufacturing line at its Le Pont-de-Claix, France site, increasing production capacity sevenfold. This expansion enhances BD's ability to meet the evolving needs of pharmaceutical partners and patients, particularly in the growing biologics segment for novel drug formulations in areas such as metabolic disorders and oncology.
BD (NYSE: BDX) ha annunciato il lancio commerciale della BD Neopak™ XtraFlow™ Siringa in Vetro Prefillabile e l'espansione della capacità della sua piattaforma BD Neopak™ Siringa in Vetro Prefillabile. Questa espansione mira a servire il crescente mercato dei biologici, con la piattaforma già approvata per oltre 24 indicazioni. La siringa XtraFlow™ presenta un ago di 8 mm e una cannula a parete sottile, ottimizzando la somministrazione di farmaci ad alta viscosità riducendo la forza e il tempo di iniezione.
BD ha anche integrato una linea di produzione ad alto volume presso il suo stabilimento di Le Pont-de-Claix, in Francia, aumentando la capacità produttiva di sette volte. Questa espansione migliora la capacità di BD di soddisfare le esigenze in evoluzione dei partner farmaceutici e dei pazienti, in particolare nel segmento in crescita dei biologici per nuove formulazioni di farmaci in aree come i disturbi metabolici e l'oncologia.
BD (NYSE: BDX) ha anunciado el lanzamiento comercial de la Jeringa de Vidrio Prefilable BD Neopak™ XtraFlow™ y la expansión de la capacidad de su plataforma de Jeringas de Vidrio Prefilables BD Neopak™. Esta expansión tiene como objetivo atender el creciente mercado de biológicos, con la plataforma ya aprobada para más de 24 indicaciones. La jeringa XtraFlow™ cuenta con una aguja de 8 mm y una cánula de pared delgada, optimizando la entrega de medicamentos de alta viscosidad al reducir la fuerza y el tiempo de inyección.
BD también ha integrado una línea de fabricación de alto volumen en su sitio de Le Pont-de-Claix, Francia, aumentando la capacidad de producción siete veces. Esta expansión mejora la capacidad de BD para satisfacer las necesidades en evolución de sus socios farmacéuticos y pacientes, particularmente en el creciente segmento de biológicos para nuevas formulaciones de medicamentos en áreas como trastornos metabólicos y oncología.
BD (NYSE: BDX)는 BD Neopak™ XtraFlow™ 유리 사전 충전 주사기의 상업적 출시와 BD Neopak™ 유리 사전 충전 주사기 플랫폼의 용량 확장을 발표했습니다. 이 확장은 증가하는 생물학적 제제 시장에 서비스를 제공하기 위해 계획되었으며, 이 플랫폼은 이미 24개 이상의 적응증에 대해 승인받았습니다. XtraFlow™ 주사기는 8mm 바늘과 얇은 벽 캔틸라를 특징으로 하여, 주입력을 줄이고 시간을 단축함으로써 고점도 약물의 전달을 최적화합니다.
BD는 또한 프랑스 레 퐁 드 클렉(Les Pont-de-Claix) 현장에서 고용량 생산 라인을 통합하여 생산 능력을 7배 증가시켰습니다. 이 확장은 BD가 제약 파트너 및 환자의 변화하는 요구를 충족할 수 있는 능력을 향상시키며, 특히 대사 질환 및 종양학과 같은 분야의 새로운 약물 제형을 위한 생물학적 제제의 성장하는 세그먼트에서 더욱 그렇습니다.
BD (NYSE: BDX) a annoncé le lancement commercial de la Seringue Préremplie en Verre BD Neopak™ XtraFlow™ et l'augmentation de la capacité de sa plateforme de seringues en verre préremplies BD Neopak™. Cette expansion vise à répondre à la demande croissante du marché des biologiques, la plateforme étant déjà approuvée pour plus de 24 indications. La seringue XtraFlow™ présente une aiguille de 8 mm et une canule à paroi fine, optimisant l'administration de médicaments à haute viscosité en réduisant la force et le temps d'injection.
BD a également intégré une ligne de fabrication à haut volume sur son site de Le Pont-de-Claix, en France, multipliant par sept la capacité de production. Cette expansion renforce la capacité de BD à répondre aux besoins évolutifs de ses partenaires pharmaceutiques et des patients, en particulier dans le segment en croissance des biologiques pour les nouvelles formulations de médicaments dans des domaines tels que les troubles métaboliques et l'oncologie.
BD (NYSE: BDX) hat die kommerzielle Einführung der BD Neopak™ XtraFlow™ Glas-Pre-Fill-Spritze sowie die Erweiterung der Kapazität seiner BD Neopak™ Glas-Pre-Fill-Spritzen-Plattform bekannt gegeben. Diese Expansion zielt darauf ab, den wachsenden Markt für Biologika zu bedienen, wobei die Plattform bereits für über 24 Indikationen zugelassen ist. Die XtraFlow™-Spritze verfügt über eine 8-mm-Nadel und eine dünnwandige Kanüle, die die Abgabe hochviskoser Medikamente optimiert, indem sie die Injektionskraft und -zeit reduziert.
BD hat außerdem eine Hochleistungsfertigungslinie an seinem Standort in Le Pont-de-Claix, Frankreich, integriert, was die Produktionskapazität verzehnfacht. Diese Expansion verbessert die Fähigkeit von BD, den sich entwickelnden Bedürfnissen von pharmazeutischen Partnern und Patienten gerecht zu werden, insbesondere im wachsenden Segment der Biologika für neuartige Arzneiformulierungen in Bereichen wie Stoffwechselstörungen und Onkologie.
- Commercial release of BD Neopak™ XtraFlow™ Glass Prefillable Syringe, optimizing delivery of high-viscosity drugs
- Expansion of BD Neopak™ Glass Prefillable Syringe platform capacity to serve growing biologics market
- Platform approved for over 24 indications, including Crohn's disease, atopic dermatitis, and cardiovascular disease
- Integration of high-volume manufacturing line, increasing production capacity sevenfold
- Enhanced ability to meet pharmaceutical partners' needs in the growing biologics segment
- None.
Insights
The launch of BD Neopak™ XtraFlow™ Glass Prefillable Syringe represents a significant advancement in drug delivery technology. With its 8mm needle and thinner wall cannula, it addresses a important challenge in biologics administration - the delivery of high-viscosity drugs. This innovation reduces injection force and time, potentially improving patient comfort and adherence.
The sevenfold increase in production capacity at the Le Pont-de-Claix facility is a game-changer. It ensures a robust supply chain for these advanced syringes, critical for meeting the growing demand in the biologics market. This expansion positions BD as a reliable partner for pharmaceutical companies developing novel biologics, particularly in high-growth areas like metabolic disorders and oncology.
BD's strategic focus on the biologics segment is well-timed. With over 30 drugs approved across 12 markets using their Neopak™ platform, they've established a strong foothold. The XtraFlow™ variant further enhances their competitive edge by addressing the specific needs of high-viscosity formulations, a growing trend in biologics.
This innovation could potentially accelerate drug development timelines and expand the range of injectable biologics. For investors, this positions BD as a key player in the
The sevenfold increase in production capacity on a single manufacturing line is a remarkable achievement in operational efficiency. This leap in productivity likely translates to significant cost savings and improved margins for BD. It also demonstrates BD's commitment to continuous improvement and lean manufacturing principles.
This efficiency gain positions BD to meet surging demand without proportional increases in capital expenditure or labor costs. For investors, this suggests potential for improved profitability and return on invested capital. Moreover, the enhanced production capacity provides BD with the flexibility to rapidly scale up in response to market demands, a important advantage in the fast-paced biologics sector.
LE PONT-DE-CLAIX,
The BD Neopak™ Glass Prefillable Syringe platform is designed to address key development needs for biologic drugs and our customers have received approval to utilize this platform for more than 24 indications, including Crohn's disease, atopic dermatitis, cardiovascular disease and various rare diseases.
BD has expanded usability of this platform with the commercial release of the BD Neopak™ XtraFlow™ Glass Prefillable Syringe. This solution features an 8-millimeter needle length and thinner wall cannula to optimize subcutaneous delivery of higher viscosity drug profiles by reducing the injection force and time required for a fixed solution viscosity1,2*. This improvement allows pharmaceutical developers to break design barriers, enhancing flow and usability beyond today's limits versus a standard half-inch needle3*.
"BD is seeing significant growth in the biologics segment, driven by novel drug formulations across indications such as metabolic disorders and oncology," said Patrick Jeukenne, president of BD Pharmaceutical Systems. "With over 30 drugs approved across 12 markets and many more in development with the BD Neopak™ Glass Prefillable Syringe platform, flexibility is crucial. As a global leader in prefillable drug-delivery systems, BD aims to evolve as rapidly as the global biologics pipeline to enable supply and delivery of these drugs for patients worldwide."
In addition to the usability enhancements, our manufacturing site in Le Pont-de-Claix,
The launch of our BD Neopak™ XtraFlow™ Glass Prefillable Syringe allows developers to take advantage of a single platform approach while dismantling existing design barriers such as drug viscosity. The successful addition of the high-volume line at the Pont-de-Claix site allows BD to be more resilient to supply constraints and further demonstrates our commitment to continuously evolve to meet the needs of our pharmaceutical partners and patients worldwide. These expansions add to BD's leadership in offering a broad range of injection solutions to enable delivery of treatments such as GLP-1s, antibodies, and other next generation treatments for chronic disease.
About BD
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its more than 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/, X (formerly Twitter) @BDandCo or Instagram @becton_dickinson.
Forward-Looking Statements
This press release contains certain forward-looking statements regarding the BD Neopak™ Glass Prefillable Syringe platform. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements, including, without limitation, challenges inherent in product development, competitive factors, including the development of new technologies or products by other companies, changes in healthcare and drug delivery, the impact of governmental regulation, future market conditions, manufacturing difficulties or delays, or other factors listed in BD's 2023 Annual Report on Form 10-K and other filings with the SEC. BD expressly disclaims any undertaking to update any forward-looking statements set forth herein to reflect events or circumstances after the date hereof, except as required by applicable laws or regulations.
Contacts: | |
Media: | Investors: |
Fallon McLoughlin | Adam Reiffe |
Director, Public Relations | Sr. Director, Investor Relations |
201.258.0361 | 201.847.6927 |
1. Injection time and ejection force calculation [internal study], Le Pont-de-Claix,
2. BD NeopakTM XtraFlowTM 2.25 mL prototype evaluation [internal study] , Le Pont-de-Claix,
3. Pager et al. (2020), "User experience for manual injection of 2 mL viscous solutions is enhanced by a new prefillable syringe with staked 8 mm ultra-thin wall needle", Expert Opinion on Drug Delivery, https://doi.org/10.1080/17425247.2020.1796630.
4. BD data on file
*When compared to 12.7 mm special thin wall needle
View original content to download multimedia:https://www.prnewswire.com/news-releases/bd-expands-capacity-for-advanced-prefillable-syringes-and-enhances-injection-experience-for-the-next-generation-of-biologics-302250865.html
SOURCE BD (Becton, Dickinson and Company)
FAQ
What new product has BD (BDX) released for biologics delivery?
How has BD (BDX) expanded its manufacturing capacity for prefillable syringes?
What are the key features of BD's (BDX) new XtraFlow™ Glass Prefillable Syringe?
How many indications has BD's (BDX) Neopak™ Glass Prefillable Syringe platform been approved for?
